Which Factors Are Relevant for Treatment Outcome in Dialectical Behaviour Therapy for Borderline Personality Disorder?
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRegion Skane
About this trial
The objective of this project is to investigate factors that contribute to the success and lack of success in DBT among individuals with BPD and a history of self-harm in a clinical psychiatric setting.
1. Do certain personality factors and identity disturbance predict the treatment outcome of DBT in individuals with BPD? 2. Do changes in identity disturbance, self-hate, or emotion regulation mediate the treatment outcome of DBT in individuals with BPD? 3. Do specific personality profiles moderate the treatment outcomes of DBT for individuals with BPD? 4. When does the primary treatment effect occur, and does this effect persist after a 12-month follow-up period?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Borderline personality disorder as defined by the DSM-V (assessed with SCID or uquivalent).
Self-harm over the past 12 months
Offered DBT at the Lund adult psychiatric clinic
Disqualifiers
Unable to read or communicate in Swedish
Trial population
Adults with Borderline personality disorder in a specialized psychiatric setting. A majority of the individuals will have comorbid psychiatric conditions and have been offered other pharmacological and psychological treatments through their GP or a general psychiatric outpatient unit prior to the study intervention. Other treatments are permitted for inclusion in this study.
Trial design
Design model
Case-only
Time perspective
Other
Treatments tested in this trial
Dialectibal Behaviour Therapy
BehavioralStandard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Individuals with BPD1 intervention
Trial outcomes
Primary outcomes
1
Five Self-harm Behaviour Groupings Measure (5S-HM)
Indirect and direct self-harm
Time frame
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.Secondary outcomes
1
The World Health Organization Disability Assessment Schedule II (WHODAS 2)
Daily functioning and impairment
Time frame
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.2
The Borderline Symptom List-23 (BSL-23)
Borderline symptoms
Time frame
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.3
The Level of Personality Functioning Scale-Brief Form 2.0 (LPFS 2.0)
Personality functioning
Time frame
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.4
The Personality Inventory for DSM-V Brief Form (PID-5-BF)
Personality structure
Time frame
Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Region Skane
Lead sponsor
Department of Psychology. Lund University.
Collaborator
University of Toronto
Collaborator
Lund University
Collaborator
Source ClinicalTrials.gov